Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ.

Cancer Treat Rev. 2019 Jun;76:57-67. doi: 10.1016/j.ctrv.2019.05.003. Epub 2019 May 15. Review.

2.

Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors.

Marcucci G, Beltrami G, Tamburini A, Body JJ, Confavreux CB, Hadji P, Holzer G, Kendler D, Napoli N, Pierroz DD, Rizzoli R, Brandi ML.

Ann Oncol. 2019 May 21. pii: mdz120. doi: 10.1093/annonc/mdz120. [Epub ahead of print]

PMID:
31111878
3.

Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort.

Baleanu F, Bergmann P, Hambye AS, Dekelver C, Iconaru L, Cappelle SI, Moreau M, Paesmans M, Karmali R, Body JJ.

Int J Clin Pract. 2019 May;73(5):e13347. doi: 10.1111/ijcp.13347. Epub 2019 Apr 17.

PMID:
30912212
4.

Meeting report of the "Symposium on kidney stones and mineral metabolism: calcium kidney stones in 2017".

Pozdzik A, Maalouf N, Letavernier E, Brocheriou I, Body JJ, Vervaet B, Van Haute C, Noels J, Gadisseur R, Castiglione V, Cotton F, Gambaro G, Daudon M, Sakhaee K.

J Nephrol. 2019 Jan 24. doi: 10.1007/s40620-019-00587-1. [Epub ahead of print]

PMID:
30680550
5.

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.

Minisola S, Marin F, Kendler DL, Geusens P, Zerbini CAF, Russo LA, Casado E, Fahrleitner-Pammer A, Stepan JJ, Lespessailles E, Moericke R, Bagur A, Lakatos P, López-Romero P, Body JJ.

Arch Osteoporos. 2019 Jan 18;14(1):10. doi: 10.1007/s11657-019-0561-x.

PMID:
30659410
6.

A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.

Body JJ, von Moos R, Rider A, Hallworth P, Bhowmik D, Gatta F, Hechmati G, Qian Y.

J Bone Oncol. 2018 Dec 18;14:100212. doi: 10.1016/j.jbo.2018.100212. eCollection 2019 Feb.

7.

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.

Henry D, von Moos R, Body JJ, Rider A, De Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y.

Curr Med Res Opin. 2019 Mar;35(3):375-381. doi: 10.1080/03007995.2018.1558849. Epub 2019 Jan 2.

PMID:
30550358
8.

Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.

Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV; MASCC Bone Study Group.

Support Care Cancer. 2019 Feb;27(2):383-394. doi: 10.1007/s00520-018-4501-x. Epub 2018 Oct 23.

PMID:
30353228
9.

Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion.

Body JJ, von Moos R, Niepel D, Tombal B.

BMC Urol. 2018 Sep 20;18(1):81. doi: 10.1186/s12894-018-0393-9. Review.

10.

Bone management in hematologic stem cell transplant recipients.

Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Rizzoli R, Ebeling PR; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease.

Osteoporos Int. 2018 Dec;29(12):2597-2610. doi: 10.1007/s00198-018-4669-4. Epub 2018 Sep 3. Review.

PMID:
30178158
11.

Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.

Qian Y, Arellano J, Gatta F, Hechmati G, Hauber AB, Mohamed AF, Bahl A, von Moos R, Body JJ.

BMC Health Serv Res. 2018 Jul 3;18(1):518. doi: 10.1186/s12913-018-3272-x.

12.

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.

von Moos R, Body JJ, Rider A, de Courcy J, Bhowmik D, Gatta F, Hechmati G, Qian Y.

J Bone Oncol. 2017 Nov 24;11:1-9. doi: 10.1016/j.jbo.2017.11.004. eCollection 2018 Jun.

13.

Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study.

von Moos R, Body JJ, Guenther O, Terpos E, Acklin YP, Finek J, Pereira J, Maniadakis N, Hechmati G, Talbot S, Sleeboom H.

J Bone Oncol. 2018 Feb 5;10:49-56. doi: 10.1016/j.jbo.2018.01.003. eCollection 2018 Mar.

14.

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.

Geusens P, Marin F, Kendler DL, Russo LA, Zerbini CA, Minisola S, Body JJ, Lespessailles E, Greenspan SL, Bagur A, Stepan JJ, Lakatos P, Casado E, Moericke R, López-Romero P, Fahrleitner-Pammer A.

J Bone Miner Res. 2018 May;33(5):783-794. doi: 10.1002/jbmr.3384. Epub 2018 Feb 9.

15.

Distribution of clinical risk factors for fracture in a Brussels cohort of postmenopausal women: The FRISBEE study and comparison with other major cohort studies.

Cappelle SI, Ramon I, Dekelver C, Rozenberg S, Baleanu F, Karmali R, Rubinstein M, Tondeur M, Moreau M, Paesmans M, Bergmann P, Body JJ.

Maturitas. 2017 Dec;106:1-7. doi: 10.1016/j.maturitas.2017.08.010. Epub 2017 Aug 24.

PMID:
29150162
16.

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.

Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.

Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9. Erratum in: Lancet. 2017 Nov 30;:. Erratum in: Lancet. 2018 Dec 1;392(10162):2352.

PMID:
29129436
17.

Skeletal health in breast cancer survivors.

Bruyère O, Bergmann P, Cavalier E, Gielen E, Goemaere S, Kaufman JM, Rozenberg S, Body JJ.

Maturitas. 2017 Nov;105:78-82. doi: 10.1016/j.maturitas.2017.08.008. Epub 2017 Aug 18. Review.

PMID:
28838807
18.

Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases.

Body JJ, Quinn G, Talbot S, Booth E, Demonty G, Taylor A, Amelio J.

Crit Rev Oncol Hematol. 2017 Jul;115:67-80. doi: 10.1016/j.critrevonc.2017.04.008. Epub 2017 Apr 23. Review.

19.

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.

Body JJ, Gatta F, De Cock E, Tao S, Kritikou P, Wimberger P, Mebis J, Peeters M, Pedrazzoli P, Caraceni A, Adamo V, Hechmati G.

Support Care Cancer. 2017 Sep;25(9):2823-2832. doi: 10.1007/s00520-017-3697-5. Epub 2017 Apr 21.

20.

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun. Review.

21.

Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.

Gielen E, Bergmann P, Bruyère O, Cavalier E, Delanaye P, Goemaere S, Kaufman JM, Locquet M, Reginster JY, Rozenberg S, Vandenbroucke AM, Body JJ.

Calcif Tissue Int. 2017 Aug;101(2):111-131. doi: 10.1007/s00223-017-0266-3. Epub 2017 Mar 21. Review.

22.

Hypercalcaemia and hypocalcaemia: finding the balance.

Body JJ, Niepel D, Tonini G.

Support Care Cancer. 2017 May;25(5):1639-1649. doi: 10.1007/s00520-016-3543-1. Epub 2017 Jan 12. Review.

23.

Pathologic fracture and healthcare resource utilisation: A retrospective study in eight European countries.

Body JJ, Acklin YP, Gunther O, Hechmati G, Pereira J, Maniadakis N, Terpos E, Finek J, von Moos R, Talbot S, Sleeboom H.

J Bone Oncol. 2016 Sep 12;5(4):185-193. doi: 10.1016/j.jbo.2016.07.003. eCollection 2016 Nov.

24.

Bone health in the elderly cancer patient: A SIOG position paper.

Body JJ, Terpos E, Tombal B, Hadji P, Arif A, Young A, Aapro M, Coleman R.

Cancer Treat Rev. 2016 Dec;51:46-53. doi: 10.1016/j.ctrv.2016.10.004. Epub 2016 Oct 27. Review.

PMID:
27863287
25.

The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Cavalier E, Bergmann P, Bruyère O, Delanaye P, Durnez A, Devogelaer JP, Ferrari SL, Gielen E, Goemaere S, Kaufman JM, Toukap AN, Reginster JY, Rousseau AF, Rozenberg S, Scheen AJ, Body JJ.

Osteoporos Int. 2016 Jul;27(7):2181-2195. doi: 10.1007/s00198-016-3561-3. Epub 2016 Mar 30.

PMID:
27026330
26.

Cost of skeletal complications from bone metastases in six European countries.

Pereira J, Body JJ, Gunther O, Sleeboom H, Hechmati G, Maniadakis N, Terpos E, Acklin YP, Finek J, von Moos R.

J Med Econ. 2016 Jun;19(6):611-8. doi: 10.3111/13696998.2016.1150852. Epub 2016 Feb 23.

PMID:
26849381
27.

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I.

Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Review.

PMID:
26681681
28.

Gorham-Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid.

Yerganyan VV, Body JJ, De Saint Aubain N, Gebhart M.

J Bone Oncol. 2015 May 16;4(2):42-6. doi: 10.1016/j.jbo.2015.05.001. eCollection 2015 Jun.

29.

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2016 Jan;24(1):457-458. doi: 10.1007/s00520-015-2985-1. No abstract available.

PMID:
26482379
30.

Effects of Dairy Products Consumption on Health: Benefits and Beliefs--A Commentary from the Belgian Bone Club and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

Rozenberg S, Body JJ, Bruyère O, Bergmann P, Brandi ML, Cooper C, Devogelaer JP, Gielen E, Goemaere S, Kaufman JM, Rizzoli R, Reginster JY.

Calcif Tissue Int. 2016 Jan;98(1):1-17. doi: 10.1007/s00223-015-0062-x. Epub 2015 Oct 7. Review.

31.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A.

Support Care Cancer. 2016 Jan;24(1):447-455. doi: 10.1007/s00520-015-2904-5. Epub 2015 Sep 3. Erratum in: Support Care Cancer. 2015 Oct 19;:.

32.

Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y.

Support Care Cancer. 2016 Mar;24(3):1327-37. doi: 10.1007/s00520-015-2908-1. Epub 2015 Sep 2.

33.

Health resource utilization associated with skeletal-related events: results from a retrospective European study.

Body JJ, Pereira J, Sleeboom H, Maniadakis N, Terpos E, Acklin YP, Finek J, Gunther O, Hechmati G, Mossman T, Costa L, Rogowski W, Nahi H, von Moos R.

Eur J Health Econ. 2016 Jul;17(6):711-21. doi: 10.1007/s10198-015-0716-7. Epub 2015 Aug 8.

34.

Targeting bone metastases in prostate cancer: improving clinical outcome.

Body JJ, Casimiro S, Costa L.

Nat Rev Urol. 2015 Jun;12(6):340-56. doi: 10.1038/nrurol.2015.90. Epub 2015 May 5. Review.

PMID:
26119830
35.

Hypocalcaemia in patients with metastatic bone disease treated with denosumab.

Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damião R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ.

Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.

36.

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A.

Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.

PMID:
25976743
37.

The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.

Schwarz P, Body JJ, Cáp J, Hofbauer LC, Farouk M, Gessl A, Kuhn JM, Marcocci C, Mattin C, Muñoz Torres M, Payer J, Van De Ven A, Yavropoulou M, Selby P.

Eur J Endocrinol. 2014 Dec;171(6):727-35. doi: 10.1530/EJE-14-0355. Epub 2014 Sep 20.

PMID:
25240499
38.

Patient preferences for treatments to delay bone metastases.

Hauber AB, Arellano J, Qian Y, González JM, Posner JD, Mohamed AF, Gatta F, Tombal B, Body JJ.

Prostate. 2014 Nov;74(15):1488-97. doi: 10.1002/pros.22865. Epub 2014 Aug 17.

PMID:
25132622
39.

Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom.

Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, Haynes I, Bahl A, von Moos R, Body JJ.

Support Care Cancer. 2015 Jan;23(1):21-8. doi: 10.1007/s00520-014-2309-x. Epub 2014 Jun 18.

40.

Bone health in cancer patients: ESMO Clinical Practice Guidelines.

Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J; ESMO Guidelines Working Group.

Ann Oncol. 2014 Sep;25 Suppl 3:iii124-37. doi: 10.1093/annonc/mdu103. Epub 2014 Apr 29.

PMID:
24782453
41.

[Inhibition of RANK ligand to treat bone metastases].

Body JJ.

Bull Cancer. 2013 Nov;100(11):1207-13. doi: 10.1684/bdc.2013.1835. Review. French.

PMID:
24158618
42.

Cancer-associated bone disease.

Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, Glüer CC, Kendler D, Napoli N, Papaioannou A, Pierroz DD, Rahme M, Van Poznak CH, de Villiers TJ, El Hajj Fuleihan G; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease.

Osteoporos Int. 2013 Dec;24(12):2929-53. doi: 10.1007/s00198-013-2530-3. Epub 2013 Oct 22. Review.

43.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.

PMID:
23975226
44.

Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials.

Coleman RE, Lipton A, Costa L, Cook RJ, Lee KA, Saad F, Brown JE, Terpos E, Major PP, Kohno N, Smith M, Body JJ.

J Bone Oncol. 2013 Feb 9;2(2):70-6. doi: 10.1016/j.jbo.2013.01.002. eCollection 2013 Jun.

45.

Health technology assessment in osteoporosis.

Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, Body JJ, Boonen S, Bruyere O, Devogelaer JP, Goemaere S, Kaufman JM, Rozenberg S, Reginster JY.

Calcif Tissue Int. 2013 Jul;93(1):1-14. doi: 10.1007/s00223-013-9724-8. Epub 2013 Mar 21. Review.

46.

Reducing the burden of bone metastases: current concepts and treatment options.

von Moos R, Sternberg C, Body JJ, Bokemeyer C.

Support Care Cancer. 2013 Jun;21(6):1773-83. doi: 10.1007/s00520-013-1755-1. Epub 2013 Mar 7. Review.

PMID:
23468364
47.

The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.

Body JJ, Chevalier P, Gunther O, Hechmati G, Lamotte M.

J Med Econ. 2013;16(4):539-46. doi: 10.3111/13696998.2013.774279. Epub 2013 Feb 21.

PMID:
23425250
48.

Health state utilities for skeletal-related events secondary to bone metastases.

Matza LS, Chung K, Van Brunt K, Brazier JE, Braun A, Currie B, Palsgrove A, Davies E, Body JJ.

Eur J Health Econ. 2014 Jan;15(1):7-18. doi: 10.1007/s10198-012-0443-2. Epub 2013 Jan 25.

49.

Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence.

Soyfoo MS, Brenner K, Paesmans M, Body JJ.

Support Care Cancer. 2013 May;21(5):1415-9. doi: 10.1007/s00520-012-1683-5. Epub 2012 Dec 11.

PMID:
23229654
50.

Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.

Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R.

Clin Oncol (R Coll Radiol). 2013 Apr;25(4):217-26. doi: 10.1016/j.clon.2012.11.004. Epub 2012 Dec 6.

PMID:
23219232

Supplemental Content

Support Center